Skip to content

Author

Omer Kucuk

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Efficacy and Safety of Every Other Week Gemcitabine and Docetaxel (GEMDOC) in Heavily Pretreated Metastatic Castration Resistant Prostate Cancer: A Retrospective Real-world Analysis.

INTRODUCTION/BACKGROUND Metastatic castration resistant prostate cancer (mCRPC) is a life-limiting phase marked by progression despite androgen deprivation therapy (ADT) with a median overall survival (OS) of approximately 25 months. Gemcitabine plus docetaxel (GEMDOC) has antitumor activity in other solid tumors, but...

J. Ciuro, Ahmet Yildirim, Yuan Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.